OTCMKTS:ZLDPF Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis $126.53 +2.45 (+1.97%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$125.75▼$126.5350-Day Range$118.57▼$141.7452-Week Range$38.92▼$141.74Volume291 shsAverage Volume2,146 shsMarket Capitalization$6.52 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Get Zealand Pharma A/S alerts: Email Address Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About Zealand Pharma A/S Stock (OTCMKTS:ZLDPF)Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.Read More ZLDPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZLDPF Stock News HeadlinesAugust 20, 2024 | markets.businessinsider.comJefferies Remains a Buy on Zealand Pharma (ZLDPF)August 16, 2024 | msn.comZealand Pharma wants a big partner for its weight loss drugSeptember 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankAugust 15, 2024 | markets.businessinsider.comZealand Pharma A-S earnings: here's what to expectAugust 15, 2024 | reuters.comZealand Pharma seeks big pharma partners for obesity drug candidateAugust 14, 2024 | markets.businessinsider.comDestiny Pharma initiates research to explore XF drug potential for CFAugust 12, 2024 | msn.comFSD Pharma Rebrands As Quantum BioPharma: Major Share Consolidation AnnouncedAugust 12, 2024 | globenewswire.comZealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial resultsSeptember 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankAugust 3, 2024 | finance.yahoo.comZealand Pharma A/S (22Z.MU)July 29, 2024 | globenewswire.comZealand Pharma Appoints Eric Cox as Chief Commercial OfficerJuly 24, 2024 | businessinsider.com4 high-conviction stock picks from top ETF managers — including GMO and a fund up 90% since 2022July 19, 2024 | finance.yahoo.comHere's What Could Help Zealand Pharma AS (ZLDPF) Maintain Its Recent Price StrengthJune 21, 2024 | cnbc.comWeight loss drug contender Zealand Pharma jumps 23% on trial resultsJune 20, 2024 | reuters.comZealand Pharma's drug reduces weight by 8.6% in early-stage studyJune 6, 2024 | reuters.comZealand Pharma says drug shows improvement in fatty liver disease patientsMay 27, 2024 | msn.com'Not just a harmless medicine': Pharmacist concerned about safety as pseudoephedrine back on shelvesMay 23, 2024 | marketwatch.comZealand Pharma Reports Low-Dose Results for New Obesity DrugSee More Headlines Receive ZLDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/15/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ZLDPF Previous SymbolNASDAQ:ZLDPF CUSIPN/A CIKN/A Webwww.zealandpharma.com Phone45-8877-3600Fax45-8877-3898Employees340Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,180,000.00 Net Margins-191.92% Pretax Margin-215.55% Return on Equity-33.94% Return on Assets-27.39% Debt Debt-to-Equity Ratio0.10 Current Ratio12.30 Quick Ratio12.28 Sales & Book Value Annual Sales$49.75 million Price / Sales131.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.49 per share Price / Book28.18Miscellaneous Outstanding Shares51,510,000Free FloatN/AMarket Cap$6.52 billion OptionableNot Optionable Beta0.96 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Adam Sinding Steensberg M.D. (Age 50)President & CEO Comp: $1.73MMs. Henriette Wennicke (Age 41)EVP & CFO Comp: $706.47kMr. Ivan Mourits Moller (Age 52)Executive VP & COO Dr. David M. Kendall M.D. (Age 63)Chief Medical Officer and Head of R&D Mr. Mads KronborgHead of Investor Relations & CommunicationMr. Ravinder Singh Chahil (Age 56)EVP & General Counsel Ms. Christina Sonnenborg Bredal (Age 39)Executive VP & Chief People Officer Dr. Jens Damsgaard Mikkelsen M.D.Head of Molecular PharmacologyDr. Danilo VergeHead of Global Medical AffairsLykke RomerVP & Head of Finance and AccountingMore ExecutivesKey CompetitorsTeva Pharmaceutical IndustriesNYSE:TEVABioNTechNASDAQ:BNTXBeiGeneNASDAQ:BGNEGenmab A/SNASDAQ:GMABGenmab A/SOTCMKTS:GNMSFView All Competitors ZLDPF Stock Analysis - Frequently Asked Questions How have ZLDPF shares performed this year? Zealand Pharma A/S's stock was trading at $55.65 at the beginning of 2024. Since then, ZLDPF stock has increased by 127.4% and is now trading at $126.53. View the best growth stocks for 2024 here. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (OTCMKTS:ZLDPF) issued its quarterly earnings results on Thursday, August, 15th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by $0.06. The company had revenue of $4.93 million for the quarter, compared to analysts' expectations of $0.50 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 33.94% and a negative net margin of 191.92%. How do I buy shares of Zealand Pharma A/S? Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ZLDPF) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Zealand Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.